Rodent models to evaluate anti-obesity drugs

Methods in Pharmacology and Toxicology

Volumn , Issue , 2012, Pages 351-376

  Cheetham, Sharon C ^a   Jackson, Helen C ^a  

^a RenaSci Ltd   (United Kingdom)

Author keywords

Animal models; Anti obesity drug; Body weight; Dietary induced obesity; Food intake; Obesity

Indexed keywords

ANTIOBESITY AGENT; PEPTIDE YY [3-36]; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUID INTAKE; FOOD INTAKE; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SATIETY; WEIGHT REDUCTION;

EID: 84869009393     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-62703-095-3_22     Document Type: Article

References (40)

1. World Health Organisation (2011) Obesity and overweight: IFact sheet No 311. http:// www.who.int/mediacentre/factsheets/ fs311/en/index.html . Mar 2011
2. Wu T, Gao X, Chen M, van Dam RM (2009) Long term effectiveness of diet-plus-exercise interventions vs. diet-only interventions forweight-loss: Ia meta-analysis. Obes Rev10(3):313-323
3. Dayyeh BK, Thompson CC (2011) Obesity and bariatrics for the endoscopist: Inew techniques.Therap Adv Gastroenterol 4(6):433-442
4. Dixon JB, Zimmet P, Alberti KG, Rubino F (2011) Bariatric surgery: Ian IDF statement for obese Type 2 diabetes. Arq Bras EndocrinolMetabol 55(6):367-382
5. Zac-Varghese S, Tan T, Bloom SR (2010)Hormonal interactions between gut and brain. Discov Med 10(55):543-552
6. Vickers SP, Cheetham SC (2007) Preclinicaldevelopments in anti-obesity drugs. In: IKirkham T, Cooper S (eds) Appetite and body weight: Iintegrative systems and the development of anti-obesity drugs. Academic Press, Burlington, MA, pp 323-336
7. Sargent BJ, Moore NA (2009) New central targets for the treatment of obesity. Br J Clin Pharmacol 68(6):852-860
8. Valentino MA, Lin JE, Waldman SA (2010) Central and peripheral molecular targets for anti-obesity pharmacotherapy. Clin Pharmacol Ther 87(6):652-662
9. Kennett GA, Clifton PG (2010) New approaches to the pharmacological treatment of obesity: Ican they break through the ef fi cacybarrier? Pharmacol Biochem Behav 97:63-83
10. EMEA (2010) European Medicines Agencyrecommends suspension of marketing authorization for sibutramine. http://www.ema. europa.eu/ema/index.jsp?curl= pages/news- and-events/news/2010/01/news-detail-000985.jsp
11. EMEA (2008) The European Medicines Agencyrecommends suspension of the marketing authorisationof Acomplia. htttp://www.ema.europa.eu/ema/index.jsp? curl=pages/news-and- events/news/2009/11/news-detail-000244.jsp&murl=menus/ news-and-events/news-and-events.jsp&mid=WC0b01ac058004d5c1
12. Hirst WD, Abrahamsen B, Blaney FE, CalverAR, Aloj L, Price GW, Medhurst AD (2003)Differences in the central nervous system distribution and pharmacology of the mouse5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling. Mol Pharmacol64(6):1295-1308
13. Asarian L, Geary N (2006) Modulation of appetite by gonadal steroid hormones. Philos TransR Soc Lond B Biol Sci 361(1471):1251-1263
14. Woods SC, Gotoh K, Clegg DJ (2003) Gender differences in the control of energy homeostasis. Exp Biol Med 228:1175-1180
15. Vickers SP, Jackson HC, Cheetham SC (2011) The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol164:1248-1262
16. Vickers SP, Sills S, Dickinson K, Gregory PC,Antel J, Cheetham SC (2005) Comparison of the effects of rimonabant, sibutramine and orlistat on acute food intake and in a model of dietary induced obesity in the mouse. Program No. 532.12. 2005 Neuroscience Meeting Planner, Washington, DC: ISociety for Neuroscience, Online
17. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ (1997) Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121:1758-1762
18. Kennedy AJ, Ellacott KLJ, King VL, Hasty AH (2010) Mouse models of the metabolic syndrome. Dis Model Mech 3:156-16619. Panchal SK, Brown L (2011) Rodent models for metabolic syndrome research. J Biomed Biotech. doi: I10.1155/2011/351982
19. Kanasaki K, Koya D (2011) Biology of obesity: Ilessons from animal models of obesity. doi: I10.1155/2011/197636
20. Farooqi IS, O'Rahilly S (2009) Leptin: Ia pivotal regulator of human energy homeostasis. Am J Clin Nutr 89:980S-984S
21. Ramachandrappa S, Farooqi IS (2011) Genetic approaches to understanding human obesity. J Clin Invest 121(6):2080-2086
22. Correia ML, Haynes WG (2007) Lessons from leptin's molecular biology: Ipotential therapeutic actions of recombinant leptin and leptinrelated compounds. Mini Rev Med Chem 7:31-38
23. Li S, Zhang HY, Hu CC, Lawrence F, Gallagher KE, Surapaneni A, Estrem ST, Calley JN, Varga G, Dow ER, Chen Y (2008) Assessment of diet-induced obese rats as an obesity model by comparative functional genomics. Obesity 16(4):811-818
24. Coskun T, Chen Y, Sindelar D, Heiman M (2007) Animal models to study obesity and type 2 diabetes induced by diet. In: IShafrir E (ed) Animals models of diabetes: Ifrontiers in research, 2nd edn. CRC, Boca Raton, FL, pp 349-357
25. Goor R, Hosking JD, Dennis BH, Graves KL, Waldman GT, Haynes SG (1985) Nutrient intakes among selected North American populations in the Lipid Research Clinic Prevalence Study; composition of fat intake. Am J Clin Nutr 41:299-311
26. Heal DJ, Gosden J, Smith SL (2011) The 5-HT 6 receptor as a target for developing antiobesity drugs. In: IBorsini F (ed) International review of neurobiology, vol 96, Pharmacology of 5-HT 6 receptors, Part II. Academic, Oxford, pp 73-109
27. Henderson AJ, Isherwood ML, Guzzo PR, Moore N, Luche M, Khmelnitsky Y, Rowley H, Viggers J, Cheetham S, Wierschke J (2011) Identi fi cation of the 5-HT6 antagonist AMRSIX- 1 for the treatment of obesity. Abstract No. 212. Keystone Symposium, Obesity, Keystone, 12-17 Jan 2011
28. Cheetham SC, Dickinson K, Goddard S, Guzzo P, Surman M, Tiong S, Xie D, Vickers S (2008) Effect of the MCH 1 antagonist, GW803430, on body weight, food and water intake, glucose tolerance, fat pad weight, ex vivo binding and various plasma parameters in dietary-induced obese C57BL/6J mice. Program No. 584.24. 2008 Neuroscience Meeting Planner, Washington, DC: ISociety for Neuroscience, Online
29. Kelly T, Yang W, Chen CS, Reynolds K, He J (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obesity 32(9):1431-1437
30. Dickinson K, North TJ, Anthony DM, Jones RB, Heal DJ (1998) Evaluation of a simpli fi ed cafeteria model for the induction of insulin resistant obesity in rats. Int J Obesity 22(Suppl 3):S179
31. Jackson HC, Dickinson K, Jones RB, Schumacher C, Jensen C (2004) Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats. Program No. 75.3. 2004 Neuroscience Meeting Planner, San Diego, CA: ISociety for Neuroscience, Online
32. Jackson HC, Cheetham SC, Dickinson K, Jones RB, Heal DJ, Gregory P, Antel J, McCreary A (2005) Comparison of the effects of rimonabant and sibutramine in a rat model of dietary-induced obesity. Program No. 532.13. 2005 Neuroscience Meeting Planner, Washington, DC: ISociety for Neuroscience, Online
33. Jackson HC, Cheetham SC, Gregory PC, Antel J (2007) Effect of chronic administration of topiramate and phentermine, alone and in combination, in an animal model of dietaryinduced obesity. Program No 629.15. 2007 Neuroscience Meeting Planner, San Diego, CA: ISociety for Neuroscience, Online
34. Rodgers RJ, Holch P, Tallett AJ (2010) Behavioural satiety sequence (BSS): Iseparating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol Biochem Behav 97(1):3-14
35. Jackson HC, Pleasance IM, Mitchell JM, Heal DJ (2000) Observational analysis of the effects of sibutramine, phentermine and aminorex on food intake in rats. Obes Res 8(Suppl 1):95S
36. Tallett AJ, Blundell JE, Rodgers RJ (2007) Grooming, scratching and feeding: Irole of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195(1):27-39
37. Grempler R, Thomas L, Klein T, Mark M, Jackson H, Cheetham S, Eickelmann P (2010) Weight loss induced by the potent and selective SGLT-2 inhibitor, BI 10773, is due to body fat reduction: IStudies in dietary-induced obese rats. Poster No: I1793-P, American Diabetes Association 70th Scienti fi c Sessions, Orlando, FL, 25-29 June 2010, Online
38. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ (1999) Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 126(6):1487-149540. Skill MJ, Dickinson K, Jones RB, Heal DJ (2000) Thermogenic effect of repeated sibutramine treatment in female Wistar rats. Int J Obesity 24(Suppl 1):S135
39. Saraç F, Pehlivan M, Celebi G, Saygili F, Yilmaz C, Kabalak T (2006) Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther 23(6):1016-1029
40. Stephens M, Ludgate M, Rees DA (2011) Brown fat and obesity: Ithe next big thing? Clin Endocrinol 74(6):661-670